Introduction

This page provides a comprehensive analysis of the known insider trading history of Adam R Craig. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Adam R Craig has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:US98420X1110 / X4 PHARMACEUTICALS INC WARRANTS EXP 4/12/24 0.00000000 Executive Chairman, Director 289,881
US:CTIC / CTI BioPharma Corp President and CEO, Director 0
EVP, Development & CMO 23,452
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Adam R Craig. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Trading History

This table shows the complete list of insider trades made by Adam R Craig as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-08-14 2025-08-14 4 XFOR X4 Pharmaceuticals, Inc
Common Stock
A - Award 289,881 289,881
2023-06-26 2023-06-26 4 CTIC CTI BIOPHARMA CORP
Common Stock
U - Other -31,470 0 -100.00 9.10 -286,377
2023-01-26 2023-01-24 4 CTIC CTI BIOPHARMA CORP
common stock
S - Sale X -2,117 29,440 -6.71 6.01 -12,723 176,934
2023-01-26 2023-01-24 4 CTIC CTI BIOPHARMA CORP
common stock
M - Exercise 2,117 31,557 7.19 0.84 1,781 26,543
2023-01-26 2023-01-24 4 CTIC CTI BIOPHARMA CORP
common stock
S - Sale X -83,200 29,440 -73.86 6.00 -499,200 176,640
2023-01-26 2023-01-24 4 CTIC CTI BIOPHARMA CORP
common stock
M - Exercise 83,200 112,640 282.61 0.84 69,980 94,742
2023-01-03 2023-01-03 4 CTIC CTI BIOPHARMA CORP
common stock
S - Sale X -84,683 29,440 -74.20 6.01 -509,224 177,032
2023-01-03 2023-01-03 4 CTIC CTI BIOPHARMA CORP
common stock
M - Exercise 84,683 114,123 287.65 0.84 71,227 95,989
2023-01-03 2022-12-30 4 CTIC CTI BIOPHARMA CORP
common stock
S - Sale X -4,400 29,440 -13.00 6.01 -26,444 176,934
2023-01-03 2022-12-30 4 CTIC CTI BIOPHARMA CORP
common stock
M - Exercise 4,400 33,840 14.95 0.84 3,701 28,463
2023-01-03 2022-12-30 4 CTIC CTI BIOPHARMA CORP
common stock
S - Sale X -700 29,440 -2.32 6.00 -4,204 176,787
2023-01-03 2022-12-30 4 CTIC CTI BIOPHARMA CORP
common stock
M - Exercise 700 30,140 2.38 0.84 589 25,351
2023-01-03 2022-12-30 4 CTIC CTI BIOPHARMA CORP
common stock
S - Sale X -12,000 29,440 -28.96 6.00 -72,000 176,640
2023-01-03 2022-12-30 4 CTIC CTI BIOPHARMA CORP
common stock
M - Exercise 12,000 41,440 40.76 0.84 10,093 34,855
2023-01-03 2022-12-30 4 CTIC CTI BIOPHARMA CORP
common stock
A - Award 1,579 29,440 5.67 5.11 8,066 150,394
2023-01-03 2022-12-29 4 CTIC CTI BIOPHARMA CORP
common stock
S - Sale X -13,800 27,861 -33.12 6.00 -82,800 167,166
2023-01-03 2022-12-29 4 CTIC CTI BIOPHARMA CORP
common stock
M - Exercise 13,800 41,661 49.53 0.84 11,607 35,041
2022-11-14 2022-11-10 4 CTIC CTI BIOPHARMA CORP
common stock
S - Sale X -2,700 27,861 -8.83 6.04 -16,308 168,280
2022-11-14 2022-11-10 4 CTIC CTI BIOPHARMA CORP
common stock
S - Sale X -5,800 30,561 -15.95 6.03 -34,974 184,283
2022-11-14 2022-11-10 4 CTIC CTI BIOPHARMA CORP
common stock
S - Sale X -16,396 36,361 -31.08 6.02 -98,704 218,893
2022-11-14 2022-11-10 4 CTIC CTI BIOPHARMA CORP
common stock
S - Sale X -100 52,757 -0.19 6.02 -602 317,333
2022-11-14 2022-11-10 4 CTIC CTI BIOPHARMA CORP
common stock
S - Sale X -26,700 52,857 -33.56 6.01 -160,467 317,671
2022-11-14 2022-11-10 4 CTIC CTI BIOPHARMA CORP
common stock
S - Sale X -200 79,557 -0.25 6.00 -1,201 477,740
2022-11-14 2022-11-10 4 CTIC CTI BIOPHARMA CORP
common stock
S - Sale X -136,408 79,757 -63.10 6.00 -818,448 478,542
2022-11-14 2022-11-10 4 CTIC CTI BIOPHARMA CORP
common stock
M - Exercise 188,304 216,165 675.87 0.84 158,382 181,816
2022-11-14 2022-11-09 4 CTIC CTI BIOPHARMA CORP
common stock
S - Sale X -300 27,861 -1.07 6.02 -1,804 167,584
2022-11-14 2022-11-09 4 CTIC CTI BIOPHARMA CORP
common stock
S - Sale X -7,596 28,161 -21.24 6.01 -45,652 169,248
2022-11-14 2022-11-09 4 CTIC CTI BIOPHARMA CORP
common stock
S - Sale X -46,100 35,757 -56.32 6.00 -276,600 214,542
2022-11-14 2022-11-09 4 CTIC CTI BIOPHARMA CORP
common stock
M - Exercise 53,996 81,857 193.80 0.84 45,416 68,850
2022-09-14 2022-09-12 4 CTIC CTI BIOPHARMA CORP
Common Stock
S - Sale X -242,300 27,861 -89.69 6.43 -1,557,989 179,146
2022-09-14 2022-09-12 4 CTIC CTI BIOPHARMA CORP
Common Stock
M - Exercise 242,300 270,161 869.67 0.84 203,799 227,232
2022-08-16 2022-08-16 4 CTIC CTI BIOPHARMA CORP
common stock
P - Purchase 5,000 27,861 21.87 5.50 27,500 153,236
2022-07-06 2022-07-06 4 CTIC CTI BIOPHARMA CORP
common stock
S - Sale X -18,223 22,861 -44.36 6.11 -111,343 139,681
2022-07-06 2022-07-06 4 CTIC CTI BIOPHARMA CORP
common stock
M - Exercise 18,223 41,084 79.71 0.84 15,327 34,556
2022-07-06 2022-07-05 4 CTIC CTI BIOPHARMA CORP
common stock
S - Sale X -27,000 22,861 -54.15 6.00 -162,000 137,166
2022-07-06 2022-07-05 4 CTIC CTI BIOPHARMA CORP
common stock
M - Exercise 27,000 49,861 118.11 0.84 22,710 41,938
2022-07-06 2022-07-01 4 CTIC CTI BIOPHARMA CORP
common stock
S - Sale X -27,000 22,861 -54.15 6.00 -162,000 137,166
2022-07-06 2022-07-01 4 CTIC CTI BIOPHARMA CORP
common stock
M - Exercise 27,000 49,861 118.11 0.84 22,710 41,938
2022-07-06 2022-06-30 4 CTIC CTI BIOPHARMA CORP
common stock
A - Award 6,183 22,861 37.07 2.12 13,086 48,385
2022-06-03 2022-06-03 4 CTIC CTI BIOPHARMA CORP
common stock
S - Sale X -18,223 16,678 -52.21 6.01 -109,520 100,235
2022-06-03 2022-06-03 4 CTIC CTI BIOPHARMA CORP
common stock
M - Exercise 18,223 34,901 109.26 0.84 15,327 29,355
2022-06-03 2022-06-02 4 CTIC CTI BIOPHARMA CORP
common stock
S - Sale X -27,000 16,678 -61.82 6.00 -162,000 100,068
2022-06-03 2022-06-02 4 CTIC CTI BIOPHARMA CORP
common stock
M - Exercise 27,000 43,678 161.89 0.84 22,710 36,738
2022-06-03 2022-06-01 4 CTIC CTI BIOPHARMA CORP
common stock
S - Sale X -27,000 16,678 -61.82 6.00 -162,000 100,068
2022-06-03 2022-06-01 4 CTIC CTI BIOPHARMA CORP
common stock
M - Exercise 27,000 43,678 161.89 0.84 22,710 36,738
2022-03-11 2022-03-09 4 CTIC CTI BIOPHARMA CORP
Stock Option (right to buy)
A - Award 1,115,000 1,115,000
2022-03-11 2021-12-31 4 CTIC CTI BIOPHARMA CORP
Common Stock
A - Award 3,178 16,678 23.54 2.11 6,699 35,157
2021-12-02 2021-12-02 4 CTIC CTI BIOPHARMA CORP
common stock
P - Purchase 2,178 13,500 19.24 1.52 3,321 20,588
2021-12-02 2021-12-02 4 CTIC CTI BIOPHARMA CORP
common stock
P - Purchase 1,322 11,322 13.22 1.52 2,016 17,265
2021-12-02 2021-06-30 4 CTIC CTI BIOPHARMA CORP
common stock
A - Award 5,000 10,000 100.00 2.12 10,625 21,250
2021-03-12 2021-03-10 4 CTIC CTI BIOPHARMA CORP
Stock Option (right to buy)
A - Award 800,000 800,000
2021-03-12 2020-07-01 4 CTIC CTI BIOPHARMA CORP
Common Stock
A - Award 5,000 5,000 0.98 4,900 4,900
2020-03-13 2020-03-11 4 CTIC CTI BIOPHARMA CORP
Non-qualified Stock Option
A - Award 2,320,000 2,320,000
2019-05-20 2019-05-16 4 ctic CTI BIOPHARMA CORP
Non-Qualified Stock Option (right to buy)
A - Award 1,300,000 1,300,000
2018-09-20 2018-09-18 4 ctic CTI BIOPHARMA CORP
Non-Qualified Stock Option (right to buy)
A - Award 600,000 600,000
2018-05-17 2018-05-16 4 ctic CTI BIOPHARMA CORP
Non-Qualified Stock Option (right to buy)
A - Award 475,000 475,000
2017-10-03 2017-09-29 4 ctic CTI BIOPHARMA CORP
Non-Qualified Stock Option (right to buy)
A - Award 450,000 450,000
2017-03-21 2017-03-20 4 CTIC CTI BIOPHARMA CORP
Stock Option (Right to Buy)
A - Award 1,200,000 1,200,000
2017-03-21 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share
0
2015-03-02 2015-02-27 4 SNSS SUNESIS PHARMACEUTICALS INC
Common Stock
F - Taxes -8,302 23,452 -26.14 2.22 -18,430 52,063
2015-03-02 2015-02-27 4 SNSS SUNESIS PHARMACEUTICALS INC
Common Stock
A - Award 19,031 31,754 149.58
2014-11-03 2014-10-31 4 SNSS SUNESIS PHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 140,000 140,000
2014-08-29 2014-08-27 4 SNSS SUNESIS PHARMACEUTICALS INC
Common Stock
S - Sale X -2,554 12,723 -16.72 8.00 -20,432 101,784
2014-03-04 2014-02-28 4 SNSS SUNESIS PHARMACEUTICALS INC
Stock Option Right to Buy
A - Award 140,000 140,000
2013-03-01 2013-02-28 4 SNSS SUNESIS PHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 125,000 125,000
2013-03-01 2013-02-28 4 SNSS SUNESIS PHARMACEUTICALS INC
Common Stock
A - Award 7,662 10,257 295.26
2012-03-02 2012-02-29 4 SNSS SUNESIS PHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 600,000 600,000
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)